5 pharmaceutical equipment companies to disclose earnings, 2019 results are good

Pharmaceutical Network Industry Dynamics , at present in the pharmaceutical equipment industry, many enterprises have disclosed the 2019 annual resultsDongfulong recently issued a earnings forecast, said that the company's 2019 expected to achieve attributable to shareholders of listed companies net profit of 134 million yuan - 155 million yuan, an increase of 90% to 120% over the same period last year
As for the reasons for the growth of performance, Dong Fulong said that during the reporting period, the company vigorously promote the "systematic, international, digital" development strategy, internal business integration and fine management, and actively explore the market, operating income increased from a year earlier, cost control is beginning to bear fruitIn addition, Dongfulong expects the non-recurring profit and loss to affect net profit for the reporting period to be about 55 million yuan
In addition to Dongfulong, the author root according to incomplete statistics, so far, there have been 4 pharmaceutical machine enterprises issued 2019 earnings forecast, and the performance is expected
Chutian Technology: Expected net profit growth of 10.0%-30% Year-on-Year Chutian Technology on January 20, the announcement shows that the full-year 2019 net profit is expected to be 45.45 million yuan -53.71 million yuan, up 10.0%-30% YoY
Chutian Technology said that during the reporting period, the company continued to provide medical equipment overall solutions, pharmaceutical plant project engineering general contracting (EPC) and pharmaceutical wisdom factory deep-working, in hand orders sufficient, more than 20% growth from the end of the previous year, operating income growth from the same period last year, growth rate of about 18%
Data show that Chutian Technology's main business for pharmaceutical equipment research and development, design, production, sales and service
Canaan Technology: It expects net profit to increase 50% to 80% YoY, and canaan Technology's 2019 annual results forecast show that the 2019 profit is expected to be RMB50.448 million-605.385 million in 2019, up 50% to 80% YoYThe result was the company's highest net profit in six years
Canaan Technology said that during the reporting period, the company in strict accordance with the development plans and business objectives, continue to improve the management and operation platform, actively promote endogenous growth and extended development, and gradually implement the "solid preparation intelligent factory overall solution provider" and the strategic layout of the large health industry
At the same time, during the reporting period, the company continued to increase the development of new markets and new product research and development investment, strengthen the brand effect and marketing network channel construction, and continue to promote collaborative management and quality enhancement workAmong them, the company's pharmaceutical equipment intelligent factory business, biologics pharmaceutical equipment and liquid distribution system business, smart logistics business segment business revenue growth, other business units steadily carried out, resulting in the company's operating income and net profit to maintain a steady growth
Data show that Canaan Technology's main business for pharmaceutical equipment, is the domestic solid preparation intelligent factory overall solution ssupplierThe main products include powder process equipment, solid preparation equipment and Chinese medicine extraction equipment, mainly used in the pharmaceutical industry, but also can be used in health care products, food and other health industry-related fields
Xinlai should be: the expected net profit increased 55.33% to 81.22% YoY on January 3, Xinlai Shouldwoodey disclosed the 2019 annual results forecast, from January to December 2019, the company's net profit attributable to shareholders of listed companies is expected to be 60 million yuan to 70 million yuan, an increase of 55.33% to 81.22% YoY
The company's rapid growth in main business led to a rise in the company's operating profit, which benefited from the acquisition of Shandong Bihai Packaging in 2018, the company achieved a relatively large increase in performance, the announcement said
It is understood that in 2018, Xinlai should buy 100% of Shandong Bihai PackagingFrom the 2019 semi-annual report data show that Shandong Bihai packaging to achieve operating profit of 30.11 million yuan, net profit of 25.7 million yuan, the overall profitability is stronger than Baolai stainless steel technology (Kunshan) and other subsidiaries, for the company has contributed a good income
Data show that the main business of Xinlai should be the main material for high-purity stainless steel as the main material of high-clean application materials research and development, production and sales, the main products for vacuum cavity, pipes, fittings, pump valves, flanges and so on
Tailin Bio: Net profit up 2.91% YoY, Tailin Bio's 2019 results report show that its 2019 performance is also relatively brightIn 2019, the company's operating income was RMB192 million, up 20.66% YoY, and its net profit was RMB49.62 million, up 2.91% YoY
Data show that Tailin Bio's main business for microbial testing and control technology system products, organic analysis equipment and other pharmaceutical equipment research and development, manufacturing and sales.